CAR-T ICU 2019 | CAR-T and neurotoxicity: frequency and management

Robert Hadden

Robert Hadden, BM BCh, FRCP, PhD, King’s College Hospital, London, UK, gives an overview of the adverse neurological events that can potentially result from CAR T-cell therapy. This interview took place at the CAR-T Cell Therapy and the ICU meeting in London, UK, which was organized by EuroCARTForce.

Share this video